The story of how a leading multinational pharma automated high-volume literature monitoring with DrugCard’s AI-powered platform
The Challenge: Buried in Data, Facing Compliance Risks
Before adopting DrugCard, GM Pharma’s pharmacovigilance team was overwhelmed by unmanageable workloads and compliance pressures. Within just six months, their operations faced:
- Over 123,000 articles requiring review – a manual process that took ~25 minutes per article.
- Limited capacity to detect safety-relevant articles across multiple languages and regional sources.
- Escalating compliance risks due to inconsistent monitoring across local and global markets.
- A growing need to maintain audit-ready traceability across 9 countries and 630 products.
Therefore, manual screening turned into a bottleneck, putting both team efficiency and regulatory confidence at risk.
The Solution: Automated, AI-Powered Monitoring with DrugCard
To transform their pharmacovigilance workflow, GM Pharma implemented DrugCard’s AI-driven literature monitoring solution, which automated the end-to-end review process.
DrugCard enabled the team to:
- Automate categorisation of global and local literature (PubMed + regional sources).
- Apply AI-based PV relevance detection to filter non-relevant publications instantly.
- Detect ICSRs using DrugCard’s integrated adverse reaction database.
- Generate quality control reports to maintain full audit readiness.
- Finally, use DrugCard Simple Search for rapid, ad-hoc data queries and actionable insights..
As a result, a streamlined, scalable monitoring process was achieved – turning hours of manual work into seconds of intelligent automation.
The Results: Unprecedented Efficiency and Bulletproof Compliance
Within months of deployment, GM Pharma’s team experienced transformational results:
- 88% reduction in article review time – from ~25 minutes to ~3 minutes per article.
- 123,693 articles reviewed efficiently across 9 countries.
- 630 products managed within one unified platform.
- 16 safety-related articles identified and 3 reportable cases detected.
- Thousands of hours saved, enabling a lean PV team to handle complex global workloads.
- Zero compliance issues during internal quality reviews.
DrugCard empowered GM Pharma to turn an overwhelming literature burden into a structured, scalable, and globally consistent PV process.
Ready to Achieve Similar Results?
Stop risking compliance and wasting valuable team hours. Discover how DrugCard can streamline your literature monitoring, expedite the detection of safety signals, and provide your team with complete peace of mind.
Take the next step and experience a personalised demo tailored just for you!
